Company
Headquarters: Toronto, ON, Canada
Employees: 6
CEO: Mr. Alejandro Antalich
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND02 Â N, N-dimethytryptamine that is in Phase II clinical trials for use in the treatment of depression; and BMND01 Â Ayahuasca, a product candidate in pre-clinical trials for use in the treatment of smoking addiction. Its product candidates in evaluation stage include BMND03 Â Psilocybin for treating chronic pain; BMND04 Â Mescaline for treating eating disorders and neurodegenerative diseases; and BMND05 Â 5-MeO-DMT, an anti-inflammatory product. The company is based in Toronto, Canada.
Biomind Labs, Inc. has the following listings and related stock indices.
Stock: NEO: BMND wb_incandescent